^
BRAF V600E + RNF43 mutation
CRC
cetuximab + encorafenib
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 1 week - (New C3)
BRAF V600E + RNF43 mutation
CRC
cetuximab + trametinib + dabrafenib
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 1 week - (New C3)
BRAF V600E + RNF43 mutation
CRC
cetuximab + trametinib + vemurafenib
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 1 week - (New C3)
BRAF V600E + RNF43 mutation
CRC
cetuximab + vemurafenib
Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 1 week - (New C3)
NRAS mutation
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
ESMO Open - 2 weeks - (New C3)
KRAS mutation
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
ESMO Open - 2 weeks - (New C3)
RNF43 G659fs
CRC
PI3K inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
RNF43 G659fs
CRC
mTOR inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
RNF43 659
CRC
mTOR inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
RNF43 659
CRC
PI3K inhibitor
Sensitive: D – Preclinical
Nat Commun - 2 weeks - (New D)
HER-2 amplification
CRC
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
JCO Clin Cancer Inform - 3 weeks - (New C3)
BRAF V600E
CRC
bevacizumab
Sensitive: B - Late Trials
Br J Cancer - 3 weeks - (New C3)
HER-2 G776S
CRC
afatinib
Sensitive: D – Preclinical
Sci Rep - 3 weeks - (New D)
APC mutation
CRC
HMG-CoA reductase inhibitor
Sensitive: D – Preclinical
Front Oncol - 3 weeks - (New D)
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive: A1 - Approval
No biomarker
Colon Cancer
capecitabine
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
FOLFIRI
Sensitive: A1 - Approval
No biomarker
Colon Cancer
5-fluorouracil + irinotecan
Sensitive: A1 - Approval
No biomarker
CRC
bevacizumab
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Zirabev (bevacizumab biosimilar)
Resistant: A1 - Approval
No biomarker
CRC
trifluridine / tipiracil
Sensitive: A1 - Approval
No biomarker
CRC
ziv-aflibercept IV
Sensitive: A1 - Approval
No biomarker
CRC
capecitabine
Sensitive: A1 - Approval
EGFR expression
CRC
cetuximab
Sensitive: A1 - Approval
KRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
ramucirumab
Sensitive: A1 - Approval
KRAS A146
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
Rectal Cancer
irinotecan
Sensitive: A1 - Approval
No biomarker
Colon Cancer
irinotecan
Sensitive: A1 - Approval
KRAS G13
CRC
cetuximab
Resistant: A1 - Approval
KRAS G12
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
nivolumab
Sensitive: A1 - Approval
No biomarker
CRC
regorafenib
Sensitive: A1 - Approval
KRAS K117
CRC
cetuximab
Resistant: A1 - Approval
KRAS A59
CRC
cetuximab
Resistant: A1 - Approval
KRAS G12S
CRC
panitumumab
Resistant: A1 - Approval
NRAS Q61
CRC
cetuximab
Resistant: A1 - Approval
NRAS Q61
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
panitumumab
Resistant: A1 - Approval
NRAS G13
CRC
cetuximab
Resistant: A1 - Approval
NRAS G12
CRC
panitumumab
Resistant: A1 - Approval
NRAS G12
CRC
cetuximab
Resistant: A1 - Approval
NRAS A146
CRC
cetuximab
Resistant: A1 - Approval
NRAS A146
CRC
panitumumab
Resistant: A1 - Approval
KRAS G13
CRC
panitumumab
Resistant: A1 - Approval
KRAS G61
CRC
panitumumab
Resistant: A1 - Approval
KRAS A146
CRC
panitumumab
Resistant: A1 - Approval
NRAS H117
CRC
cetuximab
Resistant: A1 - Approval
NRAS H117
CRC
panitumumab
Resistant: A1 - Approval
NRAS A59
CRC
cetuximab
Resistant: A1 - Approval
NRAS A59
CRC
panitumumab
Resistant: A1 - Approval
KRAS K117
CRC
panitumumab
Resistant: A1 - Approval
KRAS A59
CRC
panitumumab
Resistant: A1 - Approval
NRAS exon 4 mutation
CRC
panitumumab
Resistant: A1 - Approval
NRAS exon 3 mutation
CRC
panitumumab
Resistant: A1 - Approval
NRAS exon 2 mutation
CRC
panitumumab
Resistant: A1 - Approval
NRAS mutation
CRC
panitumumab
Resistant: A1 - Approval
NRAS exon 4 mutation
CRC
cetuximab
Resistant: A1 - Approval
No biomarker
CRC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Rectal Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Colon Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
CRC
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
CRC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
RAS wild-type
CRC
regorafenib
Sensitive: A1 - Approval
RAS wild-type
CRC
panitumumab
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
tislelizumab
Sensitive: A1 - Approval
No biomarker
CRC
fruquintinib
Sensitive: A1 - Approval
HER-2 positive
CRC
trastuzumab + pertuzumab
Sensitive: A1 - Approval
No biomarker
CRC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
dostarlimab
Sensitive: A2 - Guideline
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
oxaliplatin
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
NRAS mutation
CRC
cetuximab
Resistant: A2 - Guideline
KRAS G13D
CRC
panitumumab
Resistant: A2 - Guideline
KRAS G13D
CRC
cetuximab
Resistant: A2 - Guideline
No biomarker
CRC
panitumumab
Sensitive: A2 - Guideline
MSI-H/dMMR
CRC
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Rectal Cancer
nivolumab
Sensitive: A2 - Guideline
NTRK1 fusion
CRC
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
CRC
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
CRC
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Colon Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Colon Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
CRC
entrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
CRC
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
CRC
entrectinib
Sensitive: A2 - Guideline
BRAF V600E
CRC
panitumumab + encorafenib
Sensitive: A2 - Guideline
BRAF V600E
CRC
trametinib + dabrafenib + panitumumab
Sensitive: A2 - Guideline
HER-2 amplification
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 amplification
CRC
trastuzumab + lapatinib
Sensitive: A2 - Guideline
NRAS exon 2 mutation
CRC
cetuximab
Resistant: A2 - Guideline
NTRK2 fusion
Colon Cancer
larotrectinib
Sensitive: A2 - Guideline
NRAS exon 3 mutation
CRC
cetuximab
Resistant: A2 - Guideline
BRAF V600E
CRC
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
No biomarker
CRC
bevacizumab + trifluridine / tipiracil
Sensitive: A2 - Guideline
No biomarker
Colon Cancer
bevacizumab
Sensitive: A2 - Guideline
No biomarker
CRC
FOLFOXIRI
Sensitive: A2 - Guideline